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Abstract
Background: Children with high body mass index (BMI) at preschool age are at risk of developing obesity. Early
identification of factors that increase the risk of excessive weight gain could help direct preventive actions. The
intestinal microbiota and antibiotic use have been identified as potential modulators of early metabolic
programming and weight development. To test if the early microbiota composition is associated with later BMI,
and if antibiotic use modifies this association, we analysed the faecal microbiota composition at 3 months and the
BMI at 5–6 years in two cohorts of healthy children born vaginally at term in the Netherlands (N = 87) and Finland
(N = 75). We obtained lifetime antibiotic use records and measured weight and height of all children.
Results: The relative abundance of streptococci was positively and the relative abundance of bifidobacteria
negatively associated with the BMI outcome. The association was especially strong among children with a history
of antibiotic use. Bacteroides relative abundance was associated with BMI only in the children with minimal lifetime
antibiotic exposure.
Conclusions: The intestinal microbiota of infants are predictive of later BMI and may serve as an early indicator of
obesity risk. Bifidobacteria and streptococci, which are indicators of microbiota maturation in infants, are likely
candidates for metabolic programming of infants, and their influence on BMI appears to depend on later antibiotic use.
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Background
Overweight in childhood is an increasing global health
problem with complex aetiology [1] and long-term con-
sequences on the individual’s health, as it predisposes to
cardiovascular risk factors, such as diabetes, hyperlipid-
emia, and increased blood pressure [1], and represents
an important risk factor for adulthood obesity [2]. Pre-
and perinatal maternal and environmental factors are
being recognized as important contributors to the long-
term metabolic programming and weight development
of infants, and multiple lines of evidence indicate that
childhood overweight may be strongly dependent on
early-life influences [3]. The intestinal microbiota, ac-
quired initially during birth from the mother and
nurtured by breast milk, are emerging as an important
modulator of early metabolic programming.
Mouse studies indicate a causal role for the intestinal
microbiota regulating the development of growth, energy
metabolism, fat accumulation, and susceptibility to diet-
induced adiposity [4–6], a phenomenon termed
microbiota-induced obesity [7]. Intestinal microbiota
composition in infancy [8–12] and antibiotic use in early
childhood [13–17] have been repeatedly associated with
subsequent weight development in children. Mouse
studies have established that early-life microbiota disrup-
tion by antibiotics causes increased growth and adiposity
[6, 18, 19]. In addition to antibiotics, other microbiota-
disrupting factors, such as birth by Caesarean section
and short duration of breastfeeding, convey an increased
risk of overweight, which is likely mediated by the early
intestinal microbiota development [20, 21].
In mice, antibiotic-induced weight gain involves simi-
lar hormonal changes as diet-induced weight gain: in-
creased levels of leptin and decreased levels of ghrelin
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and peptide YY [6]. The common factor between an
obesogenic diet and antibiotic use is that they both
strongly alter the intestinal microbiota, which have the
capacity to regulate the host’s energy homeostasis via,
e.g., FXR and TGR5 signalling by bile acids [22, 23],
TLR4 signalling by lipopolysaccharide (LPS) [24, 25],
Angptl4/Fiaf signalling [4, 26], and gut hormone and
adipose tissue regulation by short-chain fatty acid
(SCFA) production [27]. It is thus becoming increasingly
evident that the early-life microbiota are involved in
long-lasting metabolic programming.
We have previously discovered that the early-life use
of macrolide antibiotics, which strongly modifies the
microbiota, is a prerequisite for later antibiotic-
associated increase in BMI in healthy Finnish children
[28]. We have also reported recently that long duration
of breastfeeding is negatively associated with BMI at
preschool age but only among children who did not re-
ceive antibiotics before weaning, i.e., whose microbiota
were intact [29], suggesting that the microbiota mediate
the beneficial metabolic effects of breastfeeding. We
therefore hypothesised that early microbiota compos-
ition may be associated with BMI in later childhood and
that antibiotic use may modify this effect. In children
with low lifetime antibiotic use, the early microbiota
composition may be associated with the child’s suscepti-
bility to diet-induced overweight, potentially involving
leptin sensitivity or adipocyte programming [3]. In chil-
dren with frequent lifetime antibiotic use, BMI is likely
to be influenced not only by diet but also by the antibi-
otics; the early-life microbiome may thus affect the
child’s susceptibility to both diet-induced and antibiotic-
associated weight gain.
To test these hypotheses, we monitored a total of 162
children in the Netherlands and Finland, from birth to
5–6 years of age and analysed their total faecal micro-
biota at the age of 3 months using a culture-
independent phylogenetic microarray. A consistent set
of intestinal bacteria at 3 months of age was found to
predict the BMI at 5–6 years, depending on the lifetime
antibiotic use. While country-specific microbiota com-
position was noticeable, the BMI-associated signatures
were evident independent of the geographic location.
Methods
Participants
The data consist of Dutch (N = 87) and Finnish (N = 75)
children comprising 162 children in total (Table 1).
These were selected from large longitudinal cohorts, the
Bibo cohort (N = 193) in the Netherlands and the Flora
cohort (N = 1223) in Finland, which have been reported
previously [30, 31]. The selection criteria of the original
studies included birth at term and no serious pregnancy
or birth complications. For the current study, we
selected vaginally born cases with appropriately stored
faecal sample collected at 3 months and information on
lifetime antibiotic use and BMI at 5–6 years. The chil-
dren were measured for weight and height at the age of
5 (Flora) or 6 (Bibo) years.
In the Flora study, pregnant mothers, whose infants
had increased risk for allergy (at least one parent had a
diagnosed allergic disease), were recruited at antenatal
clinics and through advertisements in the Helsinki
(Finland) suburban area. The Flora study was a probiotic
intervention study, and here, we only included infants
from the control group. The study was approved by the
ethical committee of the Helsinki region hospital district.
The Bibo study is a longitudinal study in which mothers
and their children were followed from the third trimes-
ter of pregnancy on. Pregnant women were recruited
through midwife practices in Nijmegen and surrounding
areas (the Netherlands).
The median birth weight was 3.4 kg (range 2.3–4.7 kg)
among the Finnish infants and 3.6 kg (range 2.7–4.7 kg)
among the Dutch infants. In the Finnish cohort, 39 in-
fants were first-born, and in the Dutch cohort, 23 infants
were first-born. At the age of 3 months, 12 Finnish in-
fants and 42 Dutch infants were no longer breastfed.
The sub-cohorts analysed here did not differ from the
total Flora and Bibo cohorts in terms of birth weight,
BMI, or duration of breastfeeding. In the total Flora co-
hort, the mean ± sd birth weight was 3.59 ± 0.49 kg, dur-
ation of breastfeeding was 8.42 ± 5.23 months, and BMI
at 5 years was 15.86 ± 1.38. In the total Bibo cohort, the
mean ± sd birth weight was 3.61 ± 0.47 kg, duration of
breastfeeding was 4.19 ± 2.78 months, and BMI at 6 years
was 15.64 ± 1.35.
Procedure
A faecal sample was collected from all infants at the
age of 3 months, by parents at home, as previously
detailed [30, 31]. In addition, information on weight
development from birth to 6 months of age was avail-
able for a subset of infants in both cohorts (Table 1).
Growth during the first 6 months was calculated as
change in weight from birth to age 6 months. BMI at
5–6 years was calculated based on the weight and
height measured by a paediatrician or a researcher.
Table 1 Characteristics of the cohorts (mean ± standard deviation)
Finnish Dutch
N 75 87
Birth weight (kg) 3.50 ± 0.44 3.64 ± 0.46
Growth first 6 months (kg); N 4.36 ± 075; 55 4.14 ± 0.69; 56
Duration of breastfeeding (weeks) 31.24 ± 17.19 14.18 ± 11.10
Total number of antibiotic courses 5.52 ± 4.82 2.67 ± 2.93
BMI 15.72 ± 1.54 15.75 ± 1.47
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Lifetime antibiotic use information was available for
both cohorts. For the Dutch cohort, data on antibiotic
prescriptions were obtained from clinical records from
the child’s GP. For the Finnish children, the parents
provided information on the number of antibiotic
courses the child had received every 3–6 months dur-
ing the first year, thereafter yearly in questionnaires.
The overwhelming majority of the antibiotic courses
were given to the children after the collection of the
faecal samples; only eight infants received antibiotics
before the age of 3 months (Fig. 1). The type of anti-
biotics used was not available for all infants, and
therefore, only the total number of courses was used
in the analysis. The level of antibiotic use was higher
in the Finnish cohort: the median number of courses
was 5 in the Finnish cohort and 2 in the Dutch co-
hort, corresponding to population-level data from
both countries [32].
Microbiota analysis
The faecal samples of both cohorts were processed and
analysed using a pipeline that has been used in many in-
fant and child microbiota studies [31, 33]. This included
DNA extraction using the repeated bead beating method
[34] and analysis of the microbiota composition using
the HITChip phylogenetic microarray, which contains
oligonucleotide probes for hypervariables regions on the
16S rRNA gene [35]. All samples were analysed on two
independent microarray experiments, and the data only
passed the quality control if the inter-experiment
Pearson correlation was >0.97. The signal intensities
were normalized using the fRPA method [36] and sum-
marised at different levels of phylogenetic resolution:
species, genus, and phylum, except for the Firmicutes,
which was further divided to Clostridium clusters and
Bacilli. Relative normalized signal intensities were calcu-
lated for all samples and all three levels. For the
Fig. 1 Microbiota composition of 3-month-old infants in the Dutch (a) and Finnish (b) cohorts. The 16 most abundant genus-level taxa are
shown. Colour codes are from top down on each column. Each column represents an individual child, and the squares below the columns show
the BMI of the child at 5–6 years (white = 13, black = 21) and lifetime antibiotic use (white = 0 courses, black = 8 or more courses). Asterisks indicate
infants who had received a course of antibiotics before sample collection
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analyses, only bacterial groups with >30% prevalence at
a minimum of 0.01% relative abundance were included
(Additional file 1).
Statistical analysis
Differences between the countries in bacterial relative
abundances were tested using generalised linear models
with negative binomial distribution. Associations be-
tween bacterial taxa to BMI and early growth were
tested using correlations. To adjust for the effects of
country, birth weight, breastfeeding duration, and anti-
biotic use on BMI, we calculated the deviance from the
expected BMI, based on a linear model with the afore-
mentioned variables. We then tested for a correlation
between the BMI deviance and the log-transformed rela-
tive abundances of the bacterial taxa. The models were
run using the whole data set and separately for each co-
hort to ascertain consistency in the associations. In
addition, the models were run separately for children
with minimal antibiotic exposure (0–1 lifetime courses),
and those with several antibiotic courses, to see if the as-
sociations were present regardless of antibiotic exposure.
Only associations that were significant in the total co-
hort (p < 0.05) and nearly significant (p < 0.15) in both
countries separately were considered robust. All statis-
tical analyses were conducted in R [37] using the pack-
age vegan [38]. R script for the analysis is available in
Additional file 2.
Results
Country differences
A total of 162 intestinal microbiota profiles from 3-
month-old infants in the Netherlands and Finland were
analysed in duplicate using an established phylogenetic
microarray (Fig. 1). In the analysis, a total of 115 bacter-
ial taxa (58 genus-like groups, 14 Clostridium cluster/
phylum groups, and 43 species-like groups) passed the
abundance and prevalence filter and were included.
Although the faecal samples were processed and ana-
lysed in the same pipeline and platform, the microbiota
compositions differed clearly between the countries
(Fig. 1, see Additional file 3). Out of the 115 taxa, the
relative abundance of 87 (76%) differed significantly be-
tween the countries. Country explained 13% of the inter-
individual differences in microbiota composition (p =
0.001). The most pronounced difference was the relative
abundance of the genus Bacteroides, which was at a low
level in the Dutch infants, but very abundant in some,
but not all, Finnish infants (Fig. 1, p < 0.00001). Veillo-
nella showed a similar pattern (Fig. 1, p < 0.00001). Bac-
teria related to Enterococcus formed a major component
of the microbiota in many Dutch infants, but repre-
sented a minority in the Finnish infants (Fig. 1, p <
0.00001). Bifidobacterium and Streptococcus were the
dominant taxa in the intestinal microbiota of both co-
horts with no significant cohort difference in relative
abundance (p = 0.09 and p = 0.44, respectively).
Association between early-life microbiota composition
and BMI at the age of 5–6 years
BMI distributions did not markedly differ between the
cohorts (see Additional file 4), and most children were
normal weight (BMI 14–17, according to the CDC
growth charts). In both cohorts, there were also over-
weight children (14 Dutch and 14 Finnish children with
BMI >17) and underweight children (10 Dutch and 7
Finnish children with BMI <14).
The background variables country, birth weight,
breastfeeding duration, and total lifetime antibiotic use
explained 11% of the BMI variation. The only significant
contributor to BMI was birth weight (p = 0.0005). Anti-
biotic use had a nearly significant positive association
with BMI (p = 0.06).
The relative abundance of the phylum Actinobacteria
was negatively and the relative abundance of the phylum
Firmicutes was positively associated with BMI (Table 2).
Among Actinobacteria, the most abundant genus Bifido-
bacterium—particularly the species B. infantis, B. pseu-
docatenulatum, B. longum, and B. thermophilum—was
negatively associated with BMI (Table 2, Fig. 2a). Among
Firmicutes, the class Bacilli, and particularly strepto-
cocci, were positively associated with BMI (Table 2,
Fig. 2b). However, these associations varied by antibiotic
exposure and were not present in the children with min-
imal antibiotic exposure (Table 2, Fig. 3). Among the
children with minimal antibiotic exposure, there was a
strong positive association between BMI and Bacteroi-
detes, particularly species related to Bacteroides ovatus,
Bacteroides vulgatus, and Prevotella tannerae (Table 2,
Fig. 3). Conversely, the phylum Firmicutes showed a sig-
nificant positive association with BMI only among the
children with a history of several antibiotic courses
(Table 2, Fig. 3).
Microbiota composition and early growth
The associations between BMI and microbiota com-
position were largely reflected in the associations be-
tween microbiota and early growth (Fig. 3). Early
growth was positively associated with the relative
abundance of Firmicutes at 3 months (correlation =
0.21 [0.03–0.39], p = 0.02), particularly Clostridia (0.20
[0.01–0.37], p = 0.04), and species related to Strepto-
coccus bovis (0.2 [0.02–0.39], p = 0.03).
Discussion
We compared the early-life faecal microbiota compo-
sitions in two cohorts of healthy infants and identi-
fied bacterial taxa whose relative abundances were
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Table 2 Correlations (95% confidence interval) between bacterial taxa and BMI, adjusted for birth weight and duration of breastfeeding,
in the total cohort (N = 162), in children with minimal antibiotic exposure (0–1 lifetime courses, N = 50), and children with several
antibiotic courses (N = 112).
Taxon All p Minimal AB p Several AB p
Actinobacteria −0.21 (−0.36 to −0.06) 0.01 −0.05 (−0.33 to 0.25) 0.76 −0.28 (−0.45 to −0.09) <0.01
Bifidobacterium −0.21 (−0.36 to −0.05) 0.01 −0.05 (−0.33 to 0.25) 0.76 −0.27 (−0.44 to −0.09) <0.01
Bifidobacterium infantis −0.19 (−0.34 to −0.04) 0.02 −0.05 (−0.33 to 0.25) 0.76 −0.23 (−0.4 to −0.04) 0.02
Bifidobacterium longum −0.2 (−0.34 to −0.04) 0.02 −0.04 (−0.33 to 0.25) 0.77 −0.24 (−0.41 to −0.05) 0.01
Bifidobacterium pseudocatenulatum −0.16 (−0.31 to 0) 0.05 0.04 (−0.25 to 0.33) 0.78 −0.25 (−0.42 to −0.06) 0.01
Bifidobacterium thermophilum −0.16 (−0.31 to 0) 0.05 0.06 (−0.23 to 0.34) 0.69 −0.24 (−0.41 to −0.05) 0.01
Bacteroidetes 0.05 (−0.11 to 0.2) 0.57 0.3 (0.01 to 0.55) 0.04 −0.02 (−0.21 to 0.18) 0.88
Bacteroides 0.06 (−0.1 to 0.21) 0.5 0.31 (0.02 to 0.55) 0.04 0 (−0.19 to 0.19) 0.99
Bacteroides ovatus et rel 0.05 (−0.11 to 0.2) 0.57 0.36 (0.07 to 0.59) 0.02 −0.04 (−0.23 to 0.15) 0.69
Bacteroides vulgatus et rel 0.07 (−0.09 to 0.22) 0.41 0.34 (0.06 to 0.57) 0.02 −0.01 (−0.2 to 0.18) 0.92
Prevotella tannerae et rel 0.13 (−0.03 to 0.28) 0.11 0.49 (0.23 to 0.68) 0 −0.01 (−0.2 to 0.18) 0.91
Firmicutes 0.23 (0.08 to 0.38) <0.01 −0.05 (−0.33 to 0.25) 0.76 0.34 (0.16 to 0.5) <0.01
Clostridia 0.08 (−0.09 to 0.23) 0.36 −0.26 (−0.51 to 0.03) 0.08 0.21 (0.02 to 0.39) 0.03
Lachnospira pectinoschiza et rel 0.15 (−0.01 to 0.31) 0.06 0.02 (−0.27 to 0.31) 0.9 0.23 (0.04 to 0.4) 0.02
Bacilli 0.25 (0.09 to 0.39) <0.01 0.21 (−0.09 to 0.47) 0.17 0.25 (0.06 to 0.42) 0.01
Streptococcus 0.26 (0.11 to 0.4) <0.01 0.07 (−0.22 to 0.35) 0.64 0.31 (0.13 to 0.48) <0.01
Streptococcus bovis et rel 0.24 (0.08 to 0.38) <0.01 −0.02 (−0.31 to 0.28) 0.92 0.29 (0.1 to 0.46) <0.01
Streptococcus intermedius et rel 0.22 (0.06 to 0.36) 0.01 0.23 (−0.06 to 0.49) 0.12 0.21 (0.02 to 0.38) 0.03
Streptococcus mitis 0.22 (0.06 to 0.37) 0.01 0.24 (−0.05 to 0.5) 0.1 0.21 (0.02 to 0.38) 0.03
Streptococcus mitis et rel 0.26 (0.11 to 0.41) <0.01 0.1 (−0.2 to 0.38) 0.52 0.32 (0.13 to 0.48) <0.01
Streptococcus mutans 0.18 (0.02 to 0.33) 0.03 0.18 (−0.11 to 0.45) 0.22 0.18 (−0.01 to 0.36) 0.06
Streptococcus parasanguinis 0.21 (0.05 to 0.36) 0.01 0.21 (−0.09 to 0.47) 0.17 0.21 (0.02 to 0.39) 0.03
Streptococcus pneumoniae 0.19 (0.03 to 0.34) 0.02 0.07 (−0.22 to 0.36) 0.63 0.22 (0.03 to 0.39) 0.02
Streptococcus salivarius 0.24 (0.08 to 0.39) <0.01 0.07 (−0.23 to 0.35) 0.65 0.28 (0.1 to 0.45) <0.01
Streptococcus sanguis 0.28 (0.12 to 0.42) <0.01 0.03 (−0.26 to 0.32) 0.82 0.34 (0.16 to 0.5) <0.01
a b
Fig. 2 Association between selected bifidobacteria (a) and streptococci (b) at 3 months of age and deviance from expected BMI at 5–6 years in
Finnish (red) and Dutch (blue) children. The deviance from expected is calculated based on birth weight and breastfeeding duration. See Table 2
for details. The trend lines (shading) show linear regression (95% confidence interval)
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consistently associated with later BMI in both the
Dutch and the Finnish cohort.
Children with a low relative abundance of Actinobac-
teria and a high relative abundance of Firmicutes at the
age of 3 months were likely to attain a high BMI at the
age of 5–6 years, but only if they received several
courses of antibiotics. This is in line with our earlier
finding that macrolide use in early life, which we have
shown to nearly eliminate Actinobacteria in children, is
required for the later antibiotic-associated increase in
BMI to occur [28]. These results suggest that the early-
life microbiota composition may modify the later meta-
bolic response to antibiotics. Antibiotic use is associated
with an increase in LPS-producing Gram-negative bac-
teria [28], and frequent antibiotic use may thus involve
recurrent LPS surges, similar to a high-fat diet [39]. It is
possible that the host’s metabolic responses to this de-
pend on early-life microbial exposure.
Fig. 3 Association between genus-like bacterial groups with infant growth from birth to 6 months and BMI at 5–6 years in the total cohort, separately
in the Dutch (NL) and Finnish (Fin) children and separately in children with minimal lifetime antibiotic use (minAB, 0–1 courses) and those with several
antibiotic courses (maxAB, >1 courses)
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Two Finnish studies based on another birth cohort have
noted a negative association between the relative abun-
dance of Bifidobacterium in infancy and later BMI [8, 9].
Moreover, high relative abundance of Firmicutes and low
relative abundance of bifidobacteria has been associated
with rapid growth, an obesity predictor [40], and with in-
creased adiposity in infancy [11, 41]. Here, we found the
same associations particularly among the children with a
history of antibiotic use. Streptococci, which were posi-
tively associated with early growth and later BMI, form a
significant component of the neonate gut microbiota [31]
and inhabit the small intestine in adults [42]. Their relative
abundance in faecal microbiota normally declines rapidly
during the first weeks, as they are replaced by anaerobic
bifidobacteria [31]. High relative abundance of strepto-
cocci and low relative abundance of bifidobacteria at
3 months likely reflects an altered maturation of the
microbiota. It is possible that the microbiota composition
in infancy is a reflection of, rather than a causal contribu-
tor to, the physiological, metabolic, or immunological de-
velopment of the host. There are, however, indications
that the microbiota actively participate in early-life meta-
bolic programming [4–6].
Increasing amount of evidence is indicating that bifi-
dobacteria have an important role in the host’s energy
metabolism. Rodent studies have shown that the nega-
tive metabolic effects of a high-fat diet are dependent on
a reduction in the abundance of bifidobacteria [43–45].
Indeed, a bifidogenic synbiotic has been shown to reduce
weight in overweight children [46]. Obesity and high-fat
diets induce endotoxemia, an increase in the level of cir-
culating lipopolysaccharide (LPS), which appears to be a
requirement for the associated metabolic consequences
[39, 43, 46]. Bifidobacteria may reduce systemic inflam-
mation by reducing the abundance of inflammatory
LPS-producing bacteria [45], by up-regulating tight-
junction proteins in the gut and thus reducing the
leakage of LPS and other bacterial antigens into the cir-
culation [43, 47], and by stimulating regulatory T cells
and the production of anti-inflammatory cytokines [45].
In obese adults, Bifidobacterium spp. correlate negatively
with serum LPS, cholesterol, and fat mass [48].
B. pseudocatenulatum and B. longum have previously
been shown to reduce weight gain and the metabolic ef-
fects of a high-fat diet in rodents, causing lower choles-
terol and leptin levels and improved insulin sensitivity
[45, 49–51]. The mechanism is at least partly related to
the amelioration of the diet-induced endotoxemia and
inflammation in the gut, liver, and in adipose tissue [45,
50, 51], and the deconjugation of bile acids [52], which
influences the host’s lipid metabolism and energy ex-
penditure [23]. B. pseudocatenulatum has been shown to
cause changes in the expression of hepatic genes in-
volved in lipid metabolism [53].
In previous Dutch studies, Bacteroides species, and
particularly B. fragilis have been associated with higher
BMI outcomes in later childhood [10, 12]. We found the
same association, but only in the children with minimal
antibiotic exposure. Dutch children generally use antibi-
otics less frequently than Finnish children, which may
explain why this association has previously not been ob-
served in Finnish children. Bacteroides spp. were gener-
ally more abundant in the Finnish infants.
Conclusions
While our results do not establish causation between
early-life microbiota composition and later BMI, they
show that the microbiota may represent a biomarker for
assessing individual risks of excessive weight gain. The
results support the emerging paradigm of microbiota-
dependent metabolic programming in humans.
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